share_log

Morgan Stanley Upgrades Third Harmonic Bio to Overweight, Raises Price Target to $20

Morgan Stanley Upgrades Third Harmonic Bio to Overweight, Raises Price Target to $20

摩根士丹利将Third Harmonic Bio评级升级至超配,将目标股价上调至20美元。
Benzinga ·  08/09 05:28  · 评级/大行评级

Morgan Stanley analyst Michael Ulz upgrades Third Harmonic Bio (NASDAQ:THRD) from Equal-Weight to Overweight and raises the price target from $12 to $20.

摩根士丹利分析师迈克尔・乌尔兹将Third Harmonic Bio (NASDAQ:THRD) 的评级从Equal-Weight升级至Overweight,并将目标价从12美元升至20美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发